Zai Lab Limited has initiated a phase 2 trial for its topical chronic plaque psoriasis treatment candidate, ZL-1102, which is a hydrogel formula of an IL-17 inhibitor aimed at treating milder forms of psoriasis. The trial will assess the efficacy of different doses compared to a placebo over a 16-week period in approximately 250 patients. ZL-1102 is the first IL-17-targeted topical treatment being developed for patients with less severe forms of chronic plaque psoriasis, with the hope of delivering a novel treatment option with reduced systemic toxicity commonly associated with other therapies.
Source link
Zai Lab begins topical IL-17 trial for mild to moderate psoriasis
